Dutch drug reimbursement reform stalls despite rising patient waits [Advocacy Lab]

The Netherlands has postponed the implementation of its "Future-Proof Medicines System" (Toekomstbestendig Stelsel Geneesmiddelen - TSG) until January 2028, a six-month delay from its original July 2027 target. This reform aims to streamline drug reimbursement processes and enhance patient access, yet it faces criticism amidst rising patient waiting times for new medicines, which averaged 493 days in 2025. The Dutch Health Ministry has urged constructive engagement from the pharmaceutical industry, emphasizing the need for robust evidence submissions and highlighting the potential of the EU Health Technology Assessment Regulation to shorten lead times. This delay underscores the ongoing tension between national cost containment efforts, fostering pharmaceutical innovation, and ensuring timely patient access to essential therapies.

The Dutch healthcare landscape is currently grappling with a significant setback in its efforts to reform drug reimbursement. The highly anticipated "Future-Proof Medicines System" (Toekomstbestendig Stelsel Geneesmiddelen, or TSG), designed to modernize the assessment and reimbursement of new medicines, has been postponed by six months, now slated for implementation in January 2028 instead of July 2027. This delay, confirmed by Health Minister Sophie Hermans in a letter to parliament, comes at a critical juncture, as Dutch patients already face some of the longest waiting times in Europe for access to newly approved medicines.

Data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) indicates that Dutch patients waited an average of 493 days in 2025 to access a new medicine after its approval by the European Medicines Agency (EMA). This figure highlights a persistent structural lag, particularly pronounced in areas like oncology. The postponement of the TSG, therefore, raises pertinent questions about the efficacy of current regulatory frameworks, the balance between cost control and patient access, and the legal implications for pharmaceutical companies operating within the Netherlands and the broader European Union. This article will delve into the statutory and doctrinal context of Dutch drug reimbursement, analyze the reasons and implications of the TSG delay, and offer insights for legal professionals navigating this complex environment.

The Dutch drug reimbursement system operates within a regulated market model, where the government sets the overarching framework, and private health insurers are responsible for providing and delivering healthcare services. Central to this system is the Health Insurance Act (Zorgverzekeringswet - Zvw), which defines the scope of the basic health insurance package, and the Medicines Reimbursement System (Geneesmiddelenvergoedingssysteem - GVS), a positive list of medicines eligible for reimbursement. The Minister of Health, Welfare and Sport (VWS), advised by the National Health Care Institute (Zorginstituut Nederland - ZIN), makes decisions on the inclusion of medicines in the GVS, based on therapeutic value, cost-effectiveness, and budget impact.

For new and often expensive medicines, the Netherlands employs a "lock" (sluis) mechanism, temporarily excluding them from the basic package pending detailed cost-effectiveness assessments and price negotiations between the Minister and manufacturers. This process, while intended to control expenditure, has been identified as a significant contributor to patient access delays, with medicines spending an average of 655 days in the "sluice" before reimbursement is agreed. Furthermore, the Medicines Pricing Act (Wet geneesmiddelenprijzen - WGP) sets maximum allowable prices for medicines based on an external reference pricing system, comparing prices in four reference countries (currently Belgium, France, Norway, and the United Kingdom).

At the European level, Council Directive 89/105/EEC, known as the Transparency Directive, aims to ensure transparency, objectivity, and comprehensibility in Member States' decisions regarding the pricing and reimbursement of medicinal products. While the Directive does not interfere with national decisions on pharmaceutical pricing or social security policies, it mandates procedural requirements, including deadlines for decisions (180 days for combined pricing and reimbursement decisions) and the provision of objective, verifiable criteria for refusals, along with legal remedies for applicants. These national and EU frameworks collectively shape the complex environment in which drug reimbursement reforms like the TSG are conceived and implemented.

The postponement of the Dutch TSG reform to January 2028, following a request from Zorginstituut Nederland, highlights the inherent complexities and tensions within the drug reimbursement system. While the Ministry of Health, Welfare and Sport expressed hope for constructive industry engagement, the Dutch Association of Innovative Medicines (VIG) had previously warned that the TSG risked introducing "additional hurdles and stricter requirements" unique to the Netherlands, potentially exacerbating existing patient waiting times.

The current system's inefficiencies are starkly illustrated by the average 493-day wait for new medicines in 2025, a figure that places the Netherlands among the slowest in Europe. This delay is partly attributed to the "sluice" mechanism, where medicines can be held for an average of 655 days for assessment and price negotiations. The Ministry, however, contends that the EFPIA's WAIT Indicator methodology conflates availability with access and does not fully account for factors like indication extensions or alternative therapies. They also emphasize that pricing and reimbursement decisions will increasingly leverage joint assessments under the EU Health Technology Assessment (HTA) Regulation, which is expected to shorten lead times, and urge pharmaceutical companies to submit stronger evidence earlier in the process.

Legally, the delay and the ongoing challenges underscore the delicate balance between national sovereignty in health policy and EU principles. Member States retain significant autonomy in setting drug prices and reimbursement rules, provided they adhere to the procedural transparency requirements of Directive 89/105/EEC. Pharmaceutical companies have legal recourse under this Directive if national authorities fail to meet deadlines or provide adequately reasoned decisions. The Dutch government's commitment to achieving "socially acceptable prices" for expensive drugs, as advised by ZIN, the Dutch Healthcare Authority (NZa), and the Netherlands Authority for Consumers and Markets (ACM), further complicates the landscape, signaling a continued focus on cost control. The "polder model" of consensus-based policymaking, traditionally characteristic of the Netherlands, appears to be under strain as the government adopts increasingly stringent measures to manage pharmaceutical expenditure.

The stalled Dutch drug reimbursement reform presents a multifaceted challenge for all stakeholders in the pharmaceutical ecosystem. While the "Future-Proof Medicines System" aims to enhance efficiency and patient access, its postponement, coupled with existing lengthy waiting times, signals persistent systemic hurdles. The tension between national cost containment objectives and the imperative to provide timely access to innovative medicines remains a central legal and ethical dilemma.

For legal practitioners, this environment necessitates a proactive and nuanced approach. Pharmaceutical companies must meticulously prepare and submit robust evidence dossiers, anticipating stringent cost-effectiveness assessments and prolonged negotiation periods. Understanding the procedural requirements and potential legal remedies under the EU Transparency Directive (89/105/EEC) will be crucial in challenging undue delays or unsubstantiated reimbursement denials. Furthermore, monitoring the evolving interplay between national policies and the implementation of the EU Health Technology Assessment Regulation will be vital. The coming years will likely see continued efforts to strike a balance between fiscal responsibility and patient welfare, making ongoing engagement with regulatory developments and strategic legal counsel indispensable for navigating the complexities of the Dutch pharmaceutical market.